EpimAb Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- EpimAb Biotherapeutics's estimated annual revenue is currently $7.8M per year.
- EpimAb Biotherapeutics's estimated revenue per employee is $155,000
Employee Data
- EpimAb Biotherapeutics has 50 Employees.
- EpimAb Biotherapeutics grew their employee count by 2% last year.
EpimAb Biotherapeutics's People
Name | Title | Email/Phone |
---|
EpimAb Biotherapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is EpimAb Biotherapeutics?
EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.
keywords:N/AN/A
Total Funding
50
Number of Employees
$7.8M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.8M | 50 | -7% | N/A |
#2 | $7.9M | 51 | 2% | N/A |
#3 | $11.5M | 52 | -4% | N/A |
#4 | $5.6M | 52 | 0% | N/A |
#5 | $9.8M | 54 | 0% | N/A |